At JPM26, Policy and Politics Will Loom Large for Pharma as Biotech Sees the Sun Heading into the J.P. Morgan Healthcare Conference for the past few years, industry watchers have tried to will deals into existence with effusive optimism despite…
The agreement aims to improve medicine affordability while supporting U.S.-based manufacturing and pharmaceutical innovation. Johnson & Johnson healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs…
Phase 2 studies advance following encouraging clinical data for T-cell engagers in autoimmune diseases Candid Therapeutics, Inc. a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced continued clinical progress with…
Collaboration focuses on advancing cell-specific siRNA therapies for cardiovascular disease treatment. Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration and global licensing agreement to advance a heart-targeted small…
Regulatory milestone strengthens 4Moving Biotech’s leadership in osteoarthritis drug innovation 4Moving Biotech, a clinical-stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)…
Novo Nordisk’s Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America Wegovy® pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine in a pill…
Analyses provide deeper insights into outcomes from the ALTAIR study presented at ASCO GI Natera, Inc., a global leader in cell-free DNA and precision medicine, announced that updated analyses from its ALTAIR clinical trial will be presented at the 2026…
Global Licensing Deal Sees Halozyme and Skye Bioscience Partner on Nimacimab-ENHANZE® Obesity Program Halozyme Therapeutics, Inc. and Skye Bioscience, Inc. have disclosed that they entered into a non-exclusive worldwide collaboration and licensing arrangement in December 2025. As part of this…
Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs BOSTON & DAEJEON, South Korea a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as…
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance BOSTON a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced financial guidance for full year 2026. Throughout…
CRISPR Therapeutics Delivers Comprehensive Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) for Autoimmune Diseases and Blood Cancers CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today provided updates on zugocaptagene geleucel (zugo-cel), formerly known…
Pimicotinib Gains Approval in China as First Systemic Therapy for Tenosynovial Giant Cell Tumor Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment…
